Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS with/without Carboplatin HIPEC in Advanced Ovarian Cancer
NCT02124421Phase 2Active, not recruiting
- Sponsor
- Mercy Medical Center
- Start
- Apr 2014
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Mercy Medical Center. Primary endpoints: Post-operative complication rates and Feasibility of recruitment. Started Apr 2014; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02124421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124421.